Symbols

Symbols

GANX

GANX

Micron Technology Stock Falls Despite Beating Earnings Estimates, Analysts Say the Recent 550% Price Surge Was Due for a Correction

Gain Therapeutics Presents GT-02287 Biomarker Signals and Aims for Phase 2 Start in Q3 at Roth Conference.

Thursday Mar 19, 2026

Gain Therapeutics to Present at 38th Annual ROTH Conference, CEO Gene Mack to Participate in Fireside Chat and One-on-One Meetings.

Wednesday Feb 25, 2026

Gain Therapeutics shares surge 31.10% intraday on presentation of Parkinson's Phase 1b data at Oppenheimer Conference.

Tuesday Feb 24, 2026

Gain Therapeutics shares rise 11.24% intraday after positive Phase 1b trial results for Parkinson's drug GT-02287 showing reduced CSF glucosylsphingosine levels and good tolerability.

Tuesday Feb 03, 2026

Gain Therapeutics reports 2026 Q1 revenue, Q2 revenue guidance, and Q1 net loss.

Friday Jan 16, 2026

Gain Therapeutics (GANX) down more than 50% since Dec 17

Thursday Jan 08, 2026

Gain Therapeutics: 15min Chart Triggers Bollinger Bands Narrowing, KDJ Death Cross

Wednesday Jan 07, 2026

Gain Therapeutics to Attend JPM Week Conferences, Sachs Neuroscience Innovation Forum, Demy-Colton/Informa Biotech Showcase, and LifeSci Advisors Corporate Access Event.

Tuesday Jan 06, 2026

Gain Therapeutics reports 81% decrease in GluSph with GT-02287 treatment.

Tuesday Dec 23, 2025

Gain Therapeutics' 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross

Monday Dec 22, 2025

Gain Therapeutics's 15min chart: MACD Death Cross, Bearish Marubozu indicates a downtrend.

Gain Therapeutics 15min chart triggers RSI Overbought and KDJ Death Cross signal.

Friday Dec 19, 2025

Gain Therapeutics shares surge 25.78% after hours as analysts raise price targets and maintain Buy ratings.

Gain Therapeutics shares surge 23.56% intraday after GT-02287 shows positive Phase 1b Parkinson's trial results with reduced CSF glucosylsphingosine and 79% participant continuation rate.

HC Wainwright Raises Gain Therapeutics PT to $8, Reiterates Buy Rating

Gain Therapeutics shares surge 16.44% premarket after Phase 1b trial shows first-ever GluSph reduction in Parkinson’s CSF, indicating CNS target engagement.

Gain Therapeutics shares surge 22.22% premarket after Phase 1b data show first-ever GluSph reduction in CSF.

Thursday Dec 18, 2025

Enhabit Outperforms Medical Peers This Year with 23.2% YTD Return

Gain Therapeutics reports CNS target engagement with GCase substrate reduction.